INBX Inhibrx, Inc.

Our mission is to discover and develop effective biologic treatments for people with life-threatening conditions and to evolve Inhibrx into a commercial-stage biotechnology company with a differentiated and sustainable product portfolio.

$17.95  +0.46 (2.63%)
As of 09/30/2022 15:59:50 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  08/19/2020
Outstanding shares:  39,057,686
Average volume:  698,299
Market cap:   $683,118,928
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BK1MBC3
Valuation   (See tab for details)
PE ratio:   -7.48
PB ratio:   25.61
PS ratio:   95.18
Return on equity:   -342.72%
Net income %:   -1,306.02%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy